RxDoctor Payments Data

Curtis Dubois, OD

Optometrist · Tulsa, OKNPI 1689197915

Payments from drug & device makers

$1,800in general payments, 2019–2025

Across 43 payments — averaging $41.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$732
  • AbbVie$544
  • Tarsus Pharmaceuticals, Inc.$187
  • Sun Pharmaceutical Industries Inc.$178
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$88
  • Rxsight Inc$22
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$1,800100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,800 in reported general payments places this provider in the 75th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$200,959
Medicare patients
817
Services billed
2,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine63$66,102
LumiganBimatoprost80$38,661
CombiganBrimonidine Tartrate/Timolol61$20,416
Prednisolone Acetate644$18,551
Ketorolac Tromethamine439$10,029
VyzultaLatanoprostene Bunod12$6,972
RocklatanNetarsudil Mesylat/Latanoprost19$6,395
Ofloxacin439$5,016
Latanoprost303$4,204
Travoprost18$2,216
Loteprednol Etabonate15$1,954
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,768
Difluprednate11$1,104
Brimonidine Tartrate114$901
Dorzolamide Hcl38$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$544$125,180204 claims
Bausch & Lomb Americas Inc.Vyzulta$15$6,97212 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$88$1,95415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →